Zhiyong Li
A5047776674- Thyroid Cancer Diagnosis and Treatment
- Radiopharmaceutical Chemistry and Applications
- Medical Imaging Techniques and Applications
Xuzhou Medical College
2023
The phase II/III study of donafenib was initiated when there no available treatment indicated for Chinese patients with progressive radioactive iodine-refractory differentiated thyroid cancer (RAIR-DTC). Donafenib, an oral tyrosine kinase inhibitor (TKI), showed good efficacy and tolerability in the II study. We aimed to further evaluate antitumor activity safety RAIR-DTC.This multicenter, double-blind, placebo-controlled, III enrolled 191 RAIR-DTC randomized a ratio 2:1 (300 mg twice daily,...
<div>Abstract<p>Purpose: The phase II/III study of donafenib was initiated when there no available treatment indicated for Chinese patients with progressive radioactive iodine-refractory differentiated thyroid cancer (RAIR-DTC). Donafenib, an oral tyrosine kinase inhibitor (TKI), showed good efficacy and tolerability in the II study. We aimed to further evaluate antitumour activity safety RAIR-DTC patients. Patients Methods: This multicenter, double-blind, placebo-controlled, III...
<p>Figure S1: Thyroglobulin concentrations changes for individual patients with negative thyroglobulin antibody from baseline to the end of cycle 2.</p>
<p>Figure S1: Thyroglobulin concentrations changes for individual patients with negative thyroglobulin antibody from baseline to the end of cycle 2.</p>
<div>AbstractPurpose:<p>The phase II/III study of donafenib was initiated when there no available treatment indicated for Chinese patients with progressive radioactive iodine-refractory differentiated thyroid cancer (RAIR-DTC). Donafenib, an oral tyrosine kinase inhibitor (TKI), showed good efficacy and tolerability in the II study. We aimed to further evaluate antitumor activity safety RAIR-DTC.</p>Patients Methods:<p>This multicenter, double-blind,...
<p>Figure S1: Thyroglobulin concentrations changes for individual patients with negative thyroglobulin antibody from baseline to the end of cycle 2.</p>
<div>Abstract<p>Purpose: The phase II/III study of donafenib was initiated when there no available treatment indicated for Chinese patients with progressive radioactive iodine-refractory differentiated thyroid cancer (RAIR-DTC). Donafenib, an oral tyrosine kinase inhibitor (TKI), showed good efficacy and tolerability in the II study. We aimed to further evaluate antitumour activity safety RAIR-DTC patients. Patients Methods: This multicenter, double-blind, placebo-controlled, III...
<p>Figure S1: Thyroglobulin concentrations changes for individual patients with negative thyroglobulin antibody from baseline to the end of cycle 2.</p>
<div>AbstractPurpose:<p>The phase II/III study of donafenib was initiated when there no available treatment indicated for Chinese patients with progressive radioactive iodine-refractory differentiated thyroid cancer (RAIR-DTC). Donafenib, an oral tyrosine kinase inhibitor (TKI), showed good efficacy and tolerability in the II study. We aimed to further evaluate antitumor activity safety RAIR-DTC.</p>Patients Methods:<p>This multicenter, double-blind,...
<p>Figure S1: Thyroglobulin concentrations changes for individual patients with negative thyroglobulin antibody from baseline to the end of cycle 2.</p>
<p>Figure S1: Thyroglobulin concentrations changes for individual patients with negative thyroglobulin antibody from baseline to the end of cycle 2.</p>